We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Step Toward Alzheimer's Therapy

By Biotechdaily staff writers
Posted on 08 Aug 2005
In an experiment that suggests a break-through treatment for patients with Alzheimer's disease (AD), researchers have been able for the first time to reverse the loss of memory in mice with brain degeneration. More...
Their work was reported in the July 2005 issue of Science.

The researchers genetically engineered mice to have the human gene that produces tau and gave them a molecular switch that could be turned off when the mice were fed doxycycline. While the gene was turned on, the mice were given memory tests in a water tank with a platform just below the water's surface. Since mice do not like water, they look for the platform. In this study, normal mice remembered where the platform was and would swim toward it. However, the genetically engineered mice appeared to become forgetful and to swim randomly around, not looking for the platform. After they were given doxycycline to reverse the effects of the tau protein, they began to look for the platform. Thus, their memory appeared to be restored even though their brains continued to accumulate neurofibrillary tangles.

From this, the researchers concluded that tau is involved in the loss and gain of memory through some other mechanism than the neurofibrillary brain tangles usually given the blame. Finding this mechanism may be the key to treating Alzheimer's.

"We hypothesize that there's an abnormal tau causing the malfunction of the hippocampus, a brain structure necessary for proper formation and storage of memories,” explained lead author Karen Ashe, professor of neurology at the University of Minnesota (Twin Cities, USA).

If the forms of tau that are causing the problem are found, scientists may be able to learn how they are formed and attempt to block the process or its affects or even to remove the proteins from the brain. Dr. Ashe cautions that the results found in mice are not often copied in humans.




Related Links:
U. of Minnesota

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Urine Analyzer
respons® UDS100
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.